The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | PANAMA, XELAVIRI & VALENTINO: gene expression signature for risk stratification in mCRC
Marco Germani, MD, FRCP, University of Pisa, Pisa, Italy, discusses the identification and validation of a prognostic mRNA expression signature in metastatic colorectal cancer (mCRC) using data from the PANAMA (NCT01991873), XELAVIRI (NCT01249638), and VALENTINO (NCT02476045) trials. A three-gene signature (VAV3, TDGF1, AGRN) was identified, which can stratify patients into low-risk groups with improved progression-free survival (PFS) and overall survival (OS), regardless of anti-EGFR or anti-VEGF exposure. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
